|
1
|
Hausen Zur H: Papillomaviruses in the
causation of human cancers-a brief historical account. Virology.
384:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barillot I, Horiot JC, Pigneux J, Schraub
S, Pourquier H, Daly N, Bolla M and Rozan R: Carcinoma of the
intact uterine cervix treated with radiotherapy alone: A French
cooperative study: Update and multivariate analysis of prognostics
factors. Int J Radiat Oncol Biol Phys. 38:969–978. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Logsdon MD and Eifel PJ: Figo IIIB
squamous cell carcinoma of the cervix: An analysis of prognostic
factors emphasizing the balance between external beam and
intracavitary radiation therapy. Int J Radiat Oncol Biol Phys.
43:763–775. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perez CA, Camel HM, Kuske RR, Kao MS,
Galakatos A, Hederman MA and Powers WE: Radiation therapy alone in
the treatment of carcinoma of the uterine cervix: A 20-year
experience. Gynecol Oncol. 23:127–140. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Monk BJ, Tewari KS and Koh WJ:
Multimodality therapy for locally advanced cervical carcinoma:
State of the art and future directions. J Clin Oncol. 25:2952–2965.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keys HM, Bundy BN, Stehman FB, Muderspach
LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin,
radiation, and adjuvant hysterectomy compared with radiation and
adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl
J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rose PG, Bundy BN, Watkins EB, Thigpen JT,
Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent
cisplatin-based radiotherapy and chemotherapy for locally advanced
cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peltenburg LT: Radiosensitivity of tumor
cells. Oncogenes and apoptosis. Q J Nucl Med. 44:355–364.
2000.PubMed/NCBI
|
|
10
|
Walch-Ruckheim B, Pahne-Zeppenfeld J,
Fischbach J, Wickenhauser C, Horn LC, Tharun L, Büttner R, Mallmann
P, Stern P, Kim YJ, et al: STAT3/IRF1 Pathway activation sensitizes
cervical cancer cells to chemotherapeutic drugs. Cancer Res.
76:3872–3883. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taniguchi K and Karin M: IL-6 and related
cytokines as the critical lynchpins between inflammation and
cancer. Semin Immunol. 26:54–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakajima K, Yamanaka Y, Nakae K, Kojima H,
Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M and Hirano T: A
central role for Stat3 in IL-6-induced regulation of growth and
differentiation in M1 leukemia cells. Embo J. 15:3651–3658.
1996.PubMed/NCBI
|
|
13
|
Wei LH, Kuo ML, Chen CA, Chou CH, Cheng
WF, Chang MC, Su JL and Hsieh CY: The anti-apoptotic role of
interleukin-6 in human cervical cancer is mediated by up-regulation
of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 20:5799–5809.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jee SH, Chiu HC, Tsai TF, Tsai WL, Liao
YH, Chu CY and Kuo ML: The phosphotidyl inositol 3-kinase/Akt
signal pathway is involved in interleukin-6-mediated Mcl-1
upregulation and anti-apoptosis activity in basal cell carcinoma
cells. J Invest Dermatol. 119:1121–1127. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen CL, Hsieh FC, Lieblein JC, Brown J,
Chan C, Wallace JA, Cheng G, Hall BM and Lin J: Stat3 activation in
human endometrial and cervical cancers. Br J Cancer. 96:591–599.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pattillo RA, Hussa RO, Story MT, Ruckert
AC, Shalaby MR and Mattingly RF: Tumor antigen and human chorionic
gonadotropin in CaSki cells: A new epidermoid cervical cancer cell
line. Science. 196:1456–1458. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Freedman RS, Bowen JM, Leibovitz A, Pathak
S, Siciliano MJ, Gallager HS and Giovanella BC: Characterization of
a cell line (SW756) derived from a human squamous carcinoma of the
uterine cervix. In vitro. 18:719–726. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones HW Jr, McKusick VA, Harper PS and
Wuu KD: George Otto Gey. (1899–1970). The HeLa cell and a
reappraisal of its origin. Obstet Gynecol. 38:945–949.
1971.PubMed/NCBI
|
|
19
|
Brady CS, Bartholomew JS, Burt DJ,
Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA,
Jimenez P, Ruiz-Cabello F, et al: Multiple mechanisms underlie HLA
dysregulation in cervical cancer. Tissue Antigens. 55:401–411.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vanneman M and Dranoff G: Combining
immunotherapy and targeted therapies in cancer treatment. Nat Rev
Cancer. 12:237–251. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hughes PE, Caenepeel S and Wu LC: Targeted
therapy and checkpoint immunotherapy combinations for the treatment
of cancer. Trends Immunol. 37:462–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Melero I, Berman DM, Aznar MA, Korman AJ,
Gracia Pérez JL and Haanen J: Evolving synergistic combinations of
targeted immunotherapies to combat cancer. Nat Rev Cancer.
15:457–472. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharma P and Allison JP: Immune checkpoint
targeting in cancer therapy: Toward combination strategies with
curative potential. Cell. 161:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tewari KS, Sill MW, Long HJ III, Penson
RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao
MM, et al: Improved survival with bevacizumab in advanced cervical
cancer. N Engl J Med. 370:734–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsuda N, Watari H and Ushijima K:
Chemotherapy and molecular targeting therapy for recurrent cervical
cancer. Chin J Cancer Res. 28:241–253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Karim R, Meyers C, Backendorf C, Ludigs K,
Offringa R, van Ommen GJ, Melief CJ, van der Burg SH and Boer JM:
Human papillomavirus deregulates the response of a cellular network
comprising of chemotactic and proinflammatory genes. PLoS One.
6:e178482011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schroer N, Pahne J, Walch B, Wickenhauser
C and Smola S: Molecular pathobiology of human cervical high-grade
lesions: Paracrine STAT3 activation in tumor-instructed myeloid
cells drives local MMP-9 expression. Cancer Res. 71:87–97. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pahne-Zeppenfeld J, Schröer N,
Walch-Rückheim B, Oldak M, Gorter A, Hegde S and Smola S: Cervical
cancer cell-derived interleukin-6 impairs CCR7-dependent migration
of MMP-9 expressing dendritic cells. Int J Cancer. 134:2061–2073.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Walch-Rückheim B, Mavrova R, Henning M,
Vicinus B, Kim YJ, Bohle RM, Juhasz-Böss I, Solomayer EF and Smola
S: Stromal fibroblasts induce CCL20 through IL6/C/EBPbeta to
support the recruitment of Th17 cells during cervical cancer
progression. Cancer Res. 75:5248–5259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heusinkveld M, de Vos van Steenwijk PJ,
Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T and
van der Burg SH: M2 macrophages induced by prostaglandin E2 and
IL-6 from cervical carcinoma are switched to activated M1
macrophages by CD4+ Th1 cells. J Immunol. 187:1157–1165. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zijlmans HJ, Punt S, Fleuren GJ, Trimbos
JB, Kenter GG and Gorter A: Role of IL-12p40 in cervical carcinoma.
Br J Cancer. 107:1956–1962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmidt SV, Seibert S, Walch-Rückheim B,
Vicinus B, Kamionka EM, Pahne-Zeppenfeld J, Solomayer EF, Kim YJ,
Bohle RM and Smola S: RIPK3 expression in cervical cancer cells is
required for PolyIC-induced necroptosis, IL-1α release and
efficient paracrine dendritic cell activation. Oncotarget.
6:8635–8647. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smola S: RIPK3-a predictive marker for
personalized immunotherapy? Oncoimmunology. 5:e10756952015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tanaka M and Miyajima A: Oncostatin M, a
multifunctional cytokine. Rev Physiol Biochem Pharmacol. 149:39–52.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Winder DM, Chattopadhyay A, Muralidhar B,
Bauer J, English WR, Zhang X, Karagavriilidou K, Roberts I, Pett
MR, Murphy G and Coleman N: Overexpression of the oncostatin M
receptor in cervical squamous cell carcinoma cells is associated
with a pro-angiogenic phenotype and increased cell motility and
invasiveness. J Pathol. 225:448–462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Caffarel MM and Coleman N: Oncostatin M
receptor is a novel therapeutic target in cervical squamous cell
carcinoma. J Pathol. 232:386–390. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kucia-Tran JA, Tulkki V, Smith S, Scarpini
CG, Hughes K, Araujo AM, Yan KY, Botthof J, Pérez-Gómez E,
Quintanilla M, et al: Overexpression of the oncostatin-M receptor
in cervical squamous cell carcinoma is associated with
epithelial-mesenchymal transition and poor overall survival. Br J
Cancer. 115:212–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
